Obermatt
See Similar Stocks →

Cooper

NSQ:COO · US2166485019
Health Care Equipment & SuppliesX-Large

360

28
EV / EBIT54
Price / Owner Earnings5
Owner Earnings Yield43
Dividend Yield1
Price/Sales37
EV / Gross Profit41
Price/Book65
Return on Capital45
Cash Return on Capital44
Return on Equity41
EBIT Margin63
Gross Profitability38
Cash Conversion94
Accruals58
Owner Earnings Margin50
Sales growth52
Profit Growth82
Long-Term EPS Growth41
Owner Earnings Growth18
Reinvestment26
Price momentum39
Debt load63
Refinancing51
Debt Payback13
Liquidity69
Analyst ratings26
Opinion Changes26
Price Target Upside50
Market mood55
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Cooper clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryHealth Care Equipment & Supplies
SizeX-Large
TypePublic Company
ExchangeNASDAQGS
Founded1980
Employees190
Websitecoopercos.com
ISINUS2166485019
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)S&P 500 (USA)D.J. US Health Care
Themes
Women's HealthHealth DiagnosticsOphthalmologyFertilityReproductive HealthGeneticsBiomedical EngineeringHealth CareManufacturingMedical Device

Description

The Cooper Companies, Inc. (Cooper) operates as a global medical device company. Cooper sells products in over 130 countries, and positively impacts over fifty million lives each year. The company operates through two business segments, CooperVisio…

Analysis

Middle-of-the-road

The Cooper Companies, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is expensive. The owner-earnings multiple stands at 55.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 20% a year, against analyst forecasts of 8%. The market is pricing in far more than analysts expect: heroic expectations.

Growth is moderate; the safety picture is stretched. The company scores 8/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
27
2023202420252026

All-time high

88

Jan 2023

All-time low

27

Jun 2026

Average rank

56

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
37
27
23
39
Price/Earnings
41
48
34
50
Price/Book
65
65
77
86
Dividend Yield
1
1
1
78
Value (overall)
25
59
25
64

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Cooper with its peers
NervGen Pharma
CVE:NGEN
44
CountryCanada
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Utah Medical Products
NSQ:UTMD
79
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
RxSight
NMQ:RXST
20
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Staar Surgical
NMQ:STAA
39
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
Universal Display
NSQ:OLED
84
CountryUSA
IndustrySemiconductors & Semiconductor Equipment
SizeMedium
Full Stock Analysis →
High Tide
CVE:HITI
62
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →